XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Shares [Member]
Total Teva Shareholders' Equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2022 $ 8,598 $ 57 $ 27,688 $ (12,975) $ (2,838) $ (4,128) $ 7,804 $ 794
Beginning balance, shares at Dec. 31, 2022   1,217            
Net Income (loss) (253)     (220)     (220) (33)
Other comprehensive income (loss) 127       136   136 (9)
Issuance of Shares, shares   9            
Stock-based compensation expense 32   32       32  
Ending balance at Mar. 31, 2023 8,504 $ 57 27,719 (13,194) (2,701) (4,128) 7,752 751
Ending balance, shares at Mar. 31, 2023   1,226            
Beginning balance at Dec. 31, 2023 8,126 $ 57 27,807 (13,534) (2,697) (4,128) 7,506 620
Beginning balance, shares at Dec. 31, 2023   1,227            
Net Income (loss) (419)     (139)     (139) (280)
Other comprehensive income (loss) (117)       (75)   (75) (42)
Issuance of Shares, value 1 $ 1         1  
Issuance of Shares, shares   11            
Stock-based compensation expense 28   28       28  
Proceeds from exercise of options 6   6       6  
Dividend to non-controlling interests (18)             (18)
Purchase of shares from non-controlling interests (64)   (45)   (3)   (48) (16)
Ending balance at Mar. 31, 2024 $ 7,543 $ 58 $ 27,796 $ (13,673) $ (2,775) $ (4,128) $ 7,278 $ 265
Ending balance, shares at Mar. 31, 2024   1,238